KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Gains from Investment Securities (2018 - 2025)

Historic Gains from Investment Securities for Moderna (MRNA) over the last 8 years, with Q3 2025 value amounting to -$14.0 million.

  • Moderna's Gains from Investment Securities fell 11272.73% to -$14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $72.0 million, marking a year-over-year increase of 12801.56%. This contributed to the annual value of $197.0 million for FY2024, which is 15518.21% up from last year.
  • According to the latest figures from Q3 2025, Moderna's Gains from Investment Securities is -$14.0 million, which was down 11272.73% from -$28.0 million recorded in Q2 2025.
  • Over the past 5 years, Moderna's Gains from Investment Securities peaked at $1.9 billion during Q4 2022, and registered a low of -$332.0 million during Q4 2023.
  • Over the past 5 years, Moderna's median Gains from Investment Securities value was $2.0 million (recorded in 2021), while the average stood at $176.4 million.
  • In the last 5 years, Moderna's Gains from Investment Securities soared by 460000.0% in 2022 and then tumbled by 16285.71% in 2024.
  • Over the past 5 years, Moderna's Gains from Investment Securities (Quarter) stood at $354.0 million in 2021, then surged by 450.28% to $1.9 billion in 2022, then tumbled by 117.04% to -$332.0 million in 2023, then soared by 136.75% to $122.0 million in 2024, then tumbled by 111.48% to -$14.0 million in 2025.
  • Its Gains from Investment Securities was -$14.0 million in Q3 2025, compared to -$28.0 million in Q2 2025 and -$8.0 million in Q1 2025.